U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Dublin, April 04, 2017 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Personalized Medicine - Scientific and Commercial Aspects" to their offering.
Several players are involved in the development of personalized therapy. Pharmaceutical and biotechnology companies have taken a leading role in this venture in keeping with their future role as healthcare enterprises rather than mere developers of technologies and manufacturers of medicines.
Ethical issues are involved in the development of personalized medicine mainly in the area of genetic testing. These along with social issues and consideration of race in the development of personalized medicine are discussed. Regulatory issues are discussed mainly with reference to the FDA guidelines on pharmacogenomics.
Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2016-2026.
Profiles of 320 companies involved in developing technologies for personalized medicines, along with 584 collaborations are included in the part II of the report. Finally the bibliography contains over 750 selected publications cited in the report.The report is supplemented by 80 tables and 38 figures.
Key Topics Covered:
Part I: Scientific & Commercial Aspects
Executive Summary
1. Basic Aspects
2. Molecular Diagnostics in Personalized Medicine
3. Pharmacogenetics
4. Pharmacogenomics
5. Role of Pharmacoproteomics
6. Role of Metabolomics in Personalized Medicine
7. Personalized Biological Therapies
8. Personalized Non-pharmacological Therapies
9. Personalized Medicine in Major Therapeutic Areas
10. Personalized Therapy of Cancer
11. Development of Personalized Medicine
12. Ethical, Legal and Regulatory Aspects of Personalized Medicine.
13. Commercial Aspects of Personalized Medicine
14. References
Part II: Companies
14. Companies Involved in Developing Personalized Medicine
For more information about this report visit http://www.researchandmarkets.com/research/t869km/personalized
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Genomics
